Roundhill GLP-1 & Weight Loss ETF

OZEM
ETF Ticker

-10.26%

+5.15%

NASDAQ

Equity

Global

Thematic

The Roundhill GLP-1 & Weight Loss ETF, OZEM_US, is an actively managed strategy providing exposure to Global, Thematic Equity. It is listed on the NASDAQ and has assets under management of $56.2m (as of Oct 30, 2026). The ETF trades in USD and was listed on the exchange on May 21, 2024. It has a net expense ratio of 59bps. (All data in USD as of Nov 5, 2026 unless stated.)

The investment framework steering the actively managed Roundhill GLP-1 & Weight Loss ETF targets global equities of companies developing or commercializing GLP-1 or other weight-management drugs/supplements. The adviser applies a proprietary thematic-relevance methodology informed by public disclosures, pipeline trackers, and industry research, investing ≥80% of net assets in issuers with FDA (or local regulator)-approved or Phase I–III assets. Eligibility requires minimum market cap USD 100m and average daily trading volume USD 500k to support liquidity and capacity. Portfolio construction emphasizes health-care sector concentration and may hold U.S. and non-U.S. shares and depositary receipts across small-, mid-, and large-caps; the fund is non-diversified. Weights are rebalanced at least quarterly to maintain thematic purity while managing single-issuer exposure and trading costs. Sell/trim decisions result from quarterly reweights, trial or regulatory events, pipeline repricing, deteriorating liquidity, or breaches of investability thresholds.

ETF Details

Key Facts

Issuer:
Roundhill Investments
AUM:
$56.2m (as of Oct 30, 2026)
Net Expense Ratio:
59 bps
Inception Date:
May 21, 2024
Index:
Actively managed strategy
Dividend Frequency:
N/A

Trading

Ticker:
OZEM
Exchange:
NASDAQ
ISIN:
US77926X8829
Trading Currency:
USD
Domicile:
United States

Classification & Risk

Asset Class:
Equity
Asset Region:
Global
Theme:
Thematic
Economic Development:
Global Markets
1 Year Volatility:
23.56%
3 Year Volatility:
N/A
5 Year Volatility:
N/A

Performance

TTM Dividend Yield:
1.39% (verify with issuer)
1 Month Performance:
2.32%
3 Month Performance:
-5.56%
6 Month Performance:
-2.81%
1 Year Performance:
5.15%
3 Year Performance:
N/A
5 Year Performance:
N/A
Investment Proposition

Roundhill GLP-1 & Weight Loss ETF (OZEM) targets companies linked to anti-obesity therapeutics and adjacent enablers, spanning diversified pharma, pure-play drug developers, contract manufacturers, and supply-chain providers. The actively managed approach prioritizes firms with exposure to glucagon-like peptide pathways and other weight-management modalities, allowing rotation across sub-segments as clinical and commercial landscapes develop. The opportunity set ties to durable healthcare demand and potential productivity gains, yet performance can hinge on regulatory outcomes, reimbursement decisions, competitive data, and manufacturing scale-up—introducing binary risks and event-driven volatility. Style exposures may blend large-cap defensives with earlier-stage biotech, creating a mix of stability and optionality across cycles. Use cases include a thematic satellite within health-care allocations or a targeted tilt for managers seeking exposure to potential obesity-related value chains without single-name selection. In pro-risk regimes with favorable clinical readouts or policy clarity, the fund’s theme can accelerate; tighter funding or adverse safety headlines may challenge returns. A fund-specific risk to monitor is concentration in a small number of commercial leaders, which can dominate factor and idiosyncratic risk.

ETF Analytics

Fund Discovery

4 Suggestions